Oncosenx
oncosenx.com
Actively hiring
Oncology Therapeutics
Cell & Gene Therapy
Follow
Overview
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$4.8M
2 rounds on record
Latest round
$650k
Venture round · Jul 2021 · 5 yr ago
Team
11-50
employees, estimated range
The money's age
Long since its last round
62 months since the last round · not hiring
Momentum
0/100
no fresh signals
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jul 22, 2021
Raised a round Venture round $650k · SEC Form D
Dec 22, 2017
Raised a round Convertible Note $4.1M · SEC Form D
2017
Founded
Tractionpublic signals, read monthly
Web presence
top 11%
of 133.2M domains by links, Common Crawl
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Jul 2021 | $650k | — | SEC Form D |
| Convertible Note | Dec 2017 | $4.1M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | OncoSenX, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
John LewisExecutive Officer, DirectorSEC Form D
Gary HudsonExecutive Officer, DirectorSEC Form D
Matthew ScholzExecutive Officer, DirectorSEC Form D
Eric GarciaExecutive OfficerSEC Form D
Stephen HilbertExecutive OfficerSEC Form D
Investors in similar startupsfunds that back the companies most like this one
backs 858 Therapeutics
backs Lyell
Similar startupsby what they do, their industry and backers
Actym Therapeutics is deploying its biologically brilliant bacteria drug delivery platform to treat cancer with powerful immunotherapies…
Optieum Biotechnologies is a biotechnology company that generates optimised scFvs to yield CAR-T cells with a strong anti-tumor effect. Its…
Waypoint Bio is a biotechnology company pioneering the next generation of cell therapies for solid tumors.
Signadori Bio is a preclinical stage biopharmaceutical company developing a next generation in vivo monocyte immunotherapy to treat solid…
TwoStep Therapeutics. Developing tumor-targeted therapies with broad applicability across solid tumors.
Learn about Lyell and how we are building an industry-leading clinical-stage pipeline of CAR-T cell product candidates for cancer.
Overview
The Next Generation in. OncoSenX is a late stage pre-clinical cancer company headquartered in Seattle, Washington. OncoSenX targets solid tumors based on transcriptional activity using a unique Proteo-Lipid Vehicle (PLV) and plasmid DNA.
People
John Lewis
Executive Officer, Director
Gary Hudson
Executive Officer, Director
Matthew Scholz
Executive Officer, Director
Eric Garcia
Executive Officer
Stephen Hilbert
Executive Officer
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Seattle
United States
HQ
10-50 est. staff